title: Stroke Neurologist's Perspective on the New Endovascular Trials.
abstract: Before December 2014, the only proven effective treatment for acute ischemic stroke was recombinant tissue-type plasminogen activator (r-tPA). This has now changed with the publication of the Multicenter Randomized Clinical Trial of Endovascular Treatment for Acute Ischemic Stroke in the Netherlands (MR CLEAN), Endovascular Treatment for Small Core and Anterior Circulation Proximal Occlusion With Emphasis on Minimizing CT to Recanalization Times (ESCAPE), Extending the Time for Thrombolysis in Emergency Neurological Deficits--Intra-Arterial (EXTEND IA), Solitaire With the Intention for Thrombectomy as Primary Endovascular Treatment Trial (SWIFT PRIME), and Randomized Trial of Revascularization With the Solitaire FR Device Versus Best Medical Therapy in the Treatment of Acute Stroke Due to Anterior Circulation Large Vessel Occlusion Presenting Within Eight Hours of Symptom Onset (REVASCAT) studies. We review the main results of these studies and how they inform stroke patient management going forward. The main take home points for neurologists are (1) intra-arterial thrombectomy is a potently effective treatment and should be offered to patients who have documented occlusion in the distal internal carotid or the proximal middle cerebral artery, have a relatively normal noncontrast head computed tomographic scan, severe neurological deficit, and can have intra-arterial thrombectomy within 6 hours of last seen normal; (2) benefits are clear in patients receiving r-tPA before intra-arterial thrombectomy; r-tPA should not be withheld if the patient meets criteria, and benefit in patients who do not receive r-tPA or have r-tPA exclusions requires further study; and (3) these favorable results occur when intra-arterial thrombectomy is performed in an endovascular stroke center by a coordinated multidisciplinary team that extends from the prehospital stage to the endovascular suite, minimizes time to recanalization, uses stent-retriever devices, and avoids general anesthesia. In conclusion, stroke teams, including practicing neurologists caring for patients with stroke should now provide the option for intra-arterial thrombectomy for a subset of patients with acute stroke.
authors.affiliation: From the Clinical Innovation and Research Institute, Memorial Hermann Hospital, Houston, TX (J.C.G.); and Department of Neurology, University Hospital Heidelberg, Ruprecht-Karls University, Heidelberg, Germany (W.H.). james.c.grotta@uth.tmc.edu.
authors.forename: James C
authors.initials: JC
authors.lastname: Grotta
authors.affiliation: From the Clinical Innovation and Research Institute, Memorial Hermann Hospital, Houston, TX (J.C.G.); and Department of Neurology, University Hospital Heidelberg, Ruprecht-Karls University, Heidelberg, Germany (W.H.).
authors.forename: Werner
authors.initials: W
authors.lastname: Hacke
mesh_terms: D002545:Brain Ischemia / Q000628:therapy*; D002986:Clinical Trials as Topic / Q000379:methods / Q000592:standards; D057510:Endovascular Procedures / Q000295:instrumentation / Q000379:methods*; D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D006801:Humans; D020521:Stroke / Q000628:therapy*; D017131:Thrombectomy / Q000295:instrumentation / Q000379:methods*; D010959:Tissue Plasminogen Activator / Q000627:therapeutic use*
chemical_list: D005343:Fibrinolytic Agents; D010959:Tissue Plasminogen Activator
keywords: cerebral infarction; clinical trials, randomized; thrombolytic therapy